Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance

What's the purpose of this trial?

The purpose of this study is to see whether Isatuximab can help improve kidney function of participants with monoclonal gammopathy of renal significance (MGRS). Isatuximab is approved by the Food and Drug Administration (FDA) for the treatment of adult patients with multiple myeloma, but it is not approved by the FDA to treat MGRS. This means that the use of isatuximab in this study is considered 'investigational'.

This trial is currently open and accepting patients.

Additional Trial Information

Phase 2

Enrollment: 27 patients (estimated)

View More

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.

New York


Abramson Cancer Center University of Pennsylvania

Philadelphia, PA

Not Yet Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message